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Abstract
The cytokine TNF promotes inﬂammation either directly by activating the MAPK and NF-κB signaling pathways, or
indirectly by triggering cell death. A20 is a potent anti-inﬂammatory molecule, and mutations in the gene encoding
A20 are associated with a wide panel of inﬂammatory pathologies, both in human and in the mouse. Binding of TNF
to TNFR1 triggers the NF-κB-dependent expression of A20 as part of a negative feedback mechanism preventing
sustained NF-κB activation. Apart from acting as an NF-κB inhibitor, A20 is also well-known for its ability to counteract
the cytotoxic potential of TNF. However, the mechanism by which A20 mediates this function and the exact cell death
modality that it represses have remained incompletely understood. In the present study, we provide in vitro and
in vivo evidences that deletion of A20 induces RIPK1 kinase-dependent and -independent apoptosis upon single TNF
stimulation. We show that constitutively expressed A20 is recruited to TNFR1 signaling complex (Complex I) via its
seventh zinc ﬁnger (ZF7) domain, in a cIAP1/2-dependent manner, within minutes after TNF sensing. We demonstrate
that Complex I-recruited A20 protects cells from apoptosis by stabilizing the linear (M1) ubiquitin network associated
to Complex I, a process independent of its E3 ubiquitin ligase and deubiquitylase (DUB) activities and which is
counteracted by the DUB CYLD, both in vitro and in vivo. In absence of linear ubiquitylation, A20 is still recruited to
Complex I via its ZF4 and ZF7 domains, but this time protects the cells from death by deploying its DUB activity.
Together, our results therefore demonstrate two distinct molecular mechanisms by which constitutively expressed
A20 protect cells from TNF-induced apoptosis.
Introduction
TNF is a well-established inducer of inﬂammation, and
a pharmacological target in several inﬂammatory dis-
orders1. Binding of TNF to TNFR1 induces the rapid
assembly of a membrane-bound signaling complex known
as TNFR1 Complex I. The initial binding of TRADD and
RIPK1 to the receptor allows the subsequent recruitment
of TRAF2 and of the E3 ubiquitin ligases cIAP1/2 and
LUBAC. Together, these E3s generate a dense network of
ubiquitin chains resulting in the stabilization of Complex I
and in the recruitment of the kinases that activate the
MAPKs and NF-κB signaling pathways2,3. The K63-
ubiquitin chains generated by cIAP1/2 operate as bind-
ing stations for the adapter proteins TAB2/3 and for the
recruitment of the kinase TAK1, which subsequently
activates the MAPK pathway by phosphorylation3–5. On
the other hand, the multiprotein E3 complex LUBAC
(composed of Sharpin, HOIP, and HOIL-1) docks on
these newly formed K63-linked ubiquitin chains and
further conjugates Complex I components with linear
(M1)-ubiquitin chains; in this way creating, in some cases,
hybrid K63/M1 chains2,6. The adapter protein NEMO
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binds to these M1-ubiquitin chains and brings the kinases
IKKα and IKKβ to the complex. The close proximity
between TAK1 and IKKα/β on the hybrid K63/M1 chains
permits activation of IKKα/β by TAK1, and the sub-
sequent IKKα/β-dependent activation of the NF-κB
pathway7. NEMO also enables the recruitment of the
noncanonical kinases TBK1/IKKε to the complex, which
may serve to counteract IKKα/β-mediated NF-κB activa-
tion8–10. Together, the MAPK and NF-κB pathways drive
the transcription of a large set of genes, including some
encoding prosurvival or proinﬂammatory molecules. The
ubiquitin network associated to Complex I is negatively
regulated by a subset of deubiquitylases (DUBs), including
A20 and CYLD, whose function consists in destabilizing
the signaling complex and restricting signaling to MAPKs
and NF-κB11.
The pathologic role of TNF in inﬂammatory disorders has
long been attributed to the MAPK/NF-κB-dependent
induction of proinﬂammatory mediators, but recent studies
in mice have demonstrated that TNF also indirectly causes
inﬂammation by inducing cell death, in the form of apop-
tosis and necroptosis12. Cell death is however not the
default response of most cells to TNF, and is only induced
when protective brakes in the pathway are inactivated12,13.
The NF-κB-dependent induction of prosurvival molecules
serves as a late brake protecting cells against RIPK1 kinase-
independent apoptosis, while the IKKα/β- and TBK1/IKKε-
dependent phosphorylation of RIPK1 functions as inde-
pendent early brakes preventing RIPK1 kinase-dependent
apoptosis9,10,14. Consequently, inactivation of any of these
brakes sufﬁces to switch the TNF response from survival to
caspase-8-mediated apoptosis. This involves dissociation of
TRADD or RIPK1 from Complex I and their subsequent
association with FADD and caspase-8 to form the cytosolic
Complex IIa or IIb, respectively15. Necroptosis occurs when
caspase-8 activation fails or is inhibited, and involves RIPK1
kinase-dependent recruitment of RIPK3 and MLKL to
Complex II to form the necrosome.
Mutations in the gene encoding A20 are associated with
a wide panel of inﬂammatory pathologies, both in human
and in the mouse16,17. Apart from functioning as an
inhibitor of the NF-κB pathway, A20 is also known to
potently inhibit TNF cytotoxicity18–20. This suggests that
the inﬂammatory disorders associated with mutations in
A20 may be caused, at least in part, by excessive cell death
induction. Our understanding of the anti-death role of
A20 has however remained limited. Structurally, A20
consists out of a N-terminal ovarian tumor (OTU)
domain, conferring it K48- and K63-DUB activity21–23,
and seven conserved C-terminal zinc ﬁnger (ZF) domains.
The ZF region allows recruitment of A20 to ubiquitin
scaffolds in immune signaling complexes, with ZF4 having
highest afﬁnity for K63 chains, and ZF7 preferentially
binding to M1 chains24–29. In addition, the ZF4 is also
reported to provide E3 ubiquitin ligase activity27,30–32. So
far, A20 was proposed to protect cells from apoptosis by
deubiquitylating caspase-8, and necroptosis by deubiqui-
tylating RIPK333,34. However, an inactivating mutation in
the OTU domain of A20 does not sufﬁce to switch the
TNF response from survival to apoptosis24,27,35. This is in
line with the fact that mice bearing the same A20 muta-
tion do not present any cell death phenotype25,36. Other
studies have instead proposed the prosurvival function of
A20 to be mediated by its ZF724,35,37, by binding and
protecting Complex I-associated M1-ubiquitin chains
from degradation24. It, however, remains unclear whether
a mutated ZF7 sufﬁces to switch the TNF response to
death since the authors only reported a signiﬁcant effect
of the mutation in conditions affecting additional pro-
survival brakes in the pathway, such as caspase- or protein
translation-inhibited conditions.
In this study, we further characterized the anti-death
role of A20 in the TNF pathway. We found that A20-
deﬁciency results in RIPK1 kinase-dependent and -inde-
pendent apoptosis upon single TNF stimulation, and
demonstrate two distinct mechanisms by which con-
stitutively expressed A20 protects the cells: one relying on
A20′s ability to stabilize M1-ubiquitin chains in Complex
I, and another one, revealed in absence of M1-ubiquitin
chains, which requires A20′s DUB activity.
Results
A20-deﬁciency triggers RIPK1 kinase-dependent and
-independent apoptosis upon single TNF stimulation
Although A20-deﬁciency promotes NF-κB activation
and thereby enforces a protective brake in the TNFR1
pathway, loss of A20 paradoxically sensitizes cells to TNF-
induced death. To get a better understanding of A20′s
anti-death role, we evaluated the cell death modality
induced by A20 deletion in MEFs. A20-deﬁciency was
sufﬁcient to greatly sensitize the cells to death upon single
TNF stimulation (Fig. 1a). The cell death was character-
ized by the release of active caspase-3 (Fig. 1b) and the
presence of cleaved caspase-8, caspase-3, and PARP-1 in
the cell lysates (Fig. 1c), indicative of apoptosis. Of note,
A20-deﬁciency did not sensitize MEFs to apoptosis
induced by staurosporin, etoposide, or tunicamycin (Fig.
S1A). Interestingly, we detected RIPK1 activation (mon-
itored by S166 autophosphorylation) in the lysate of TNF-
stimulated A20-deﬁcient MEFs (Fig. 1c), suggestive of
RIPK1 kinase-dependent cell death. Inhibition of RIPK1
by Necrostatin-1s (Nec1s) resulted in reduced, but not
totally inhibited, caspase activation and cell death,
demonstrating simultaneous occurrence of RIPK1 kinase-
dependent and -independent apoptosis (Fig. 1c–f).
Although hallmarks of apoptosis were primarily
detected, we also observed RIPK1 kinase-dependent
phosphorylation of MLKL on S345 (Fig. 1g), a reported
Priem et al. Cell Death and Disease          (2019) 10:692 Page 2 of 16
Ofﬁcial journal of the Cell Death Differentiation Association
Fig. 1 (See legend on next page.)
Priem et al. Cell Death and Disease          (2019) 10:692 Page 3 of 16
Ofﬁcial journal of the Cell Death Differentiation Association
marker of necroptosis38. To address if necroptosis was
simultaneously occurring in these cells, we blocked the
necroptotic pathway by knocking down RIPK3 and
MLKL. While repressing RIPK3 and MLKL effectively
repressed necroptosis induced by TNF in presence of the
pan-caspase inhibitor zVAD-fmk (zVAD) (Fig. S1B, C), it
did not signiﬁcantly inﬂuence the extent of cell death
induced by single TNF stimulation in A20−/− MEFs
(Fig. 1h, i). Single-cell analysis combining a general cell
death probe with a caspase-activity probe, also excluded
the presence of purely necrotic cells in A20−/− MEFs
stimulated with TNF (Fig. 1j, Fig. S1D, E). Together, our
results demonstrate that, despite activation of a
necroptotic marker, A20-deﬁency in MEFs triggers
RIPK1 kinase-dependent and -independent apoptosis
upon single TNF stimulation.
A20 provides in vitro and in vivo protection to intestinal
epithelial cells against TNF-induced RIPK1 kinase-
dependent and -independent apoptosis
To evaluate whether the results obtained in MEFs could
be extrapolated to other cell types and to an in vivo context,
we made use of mice speciﬁcally lacking A20 in intestinal
epithelial cells (IECs) (A20ΔIEC)39. These mice die shortly
after administrating low doses of TNF due to hyperin-
ﬂammation and/or extensive TNF-dependent death of
IECs39. We found that crossing these mice with mice
expressing kinase-dead RIPK1 (Ripk1D138N/D138N)40 pro-
vided partial protection to TNF-induced lethality. Indeed,
A20ΔIEC Ripk1D138N/D138N mice showed signiﬁcant delay in
body temperature drop and associated lethality when
compared to the A20ΔIEC Ripk1+/+ littermates (Fig. 2a, b).
This partial protection was not resulting from inhibition of
necroptosis since crossing the A20ΔIEC mice with the
Ripk3−/− mice41 did not provide any protection (Fig. S2A).
We also found that organoid cultures isolated from
A20ΔIEC mice died upon single TNF stimulation (Fig. 2c),
and that the cell death could partially be prevented by
pharmacological or genetic inhibition of RIPK1 kinase
activity (Fig. 2d–f). Taken together, these data demonstrate
a critical role for A20 in the in vitro and in vivo protection
of intestinal epithelial cells against TNF-induced RIPK1
kinase-dependent and -independent apoptosis.
Constitutively expressed A20 exerts its antideath function
through cIAP1/2-dependent recruitment to TNFR1
Complex I
A20 is an NF-κB target gene and its inhibitory role on
TNF-induced NF-κB is therefore widely seen as a
negative-feedback mechanism preventing sustained NF-
κB activation42. We found that constitutively expressed
A20 is recruited to TNFR1 Complex I within minutes of
TNF sensing (Fig. 3a), which is in line with previous
reports24,37. To evaluate whether the antideath role of
A20 originates from the constitutively expressed pool of
A20 or from the one transcriptionally upregulated, we
compared the cell death response of A20+/+ and A20−/−
MEFs to TNF in the presence of the translational inhibitor
cycloheximide (CHX). The use of CHX indeed prevents
the NF-κB-dependent induction of A20 in control MEFs
(Fig. 3b), thereby allowing speciﬁc evaluation of the
antideath role of the constitutively expressed A20.
Remarkably, A20-deﬁciency still sensitized MEFs and
HaCaT cells to RIPK1 kinase-dependent and -indepen-
dent apoptosis following TNF+CHX treatment (Fig. 3c,
Fig. S3A), which demonstrated the anti-death role of the
constitutively expressed pool of A20 that is quickly
recruited to Complex I. In addition, the cell death caused
by A20 deﬁciency was not originating from sustained NF-
κB activation, since inhibiting the NF-κB-dependent
response by CHX did not protect but instead sensitize
A20−/− cells to TNF-induced death (Fig. 3d).
To position the antideath function of A20 in Complex I,
we next evaluated the effect of A20 deletion in cells
inactivated for other crucial antideath Complex I com-
ponents, such as IKKα/β, TBK1, or the upstream reg-
ulators TAK1 and cIAP1/29,10,14,43. We found that while
A20-deﬁciency further sensitized cells in which IKKα/β,
TBK1, or TAK1 had been inactivated (alone or together)
(Fig. 3e, f, Fig. S3B, C), it did not increase the extent of
death in cells where cIAP1/2 had been inactivated either
pharmacologically or genetically (Fig. 3g, h). These results
(see ﬁgure on previous page)
Fig. 1 A20 deﬁciency in MEFs triggers RIPK1 kinase-dependent and -independent apoptosis, but not necroptosis, following single TNF
stimulation. a–g A20+/+ and A20−/− MEFs were pretreated with the indicated compounds for 30 min before stimulation with 10 ng/ml mTNF. Cell
death was measured in function of time by SytoxGreen (SG) positivity (a, d, f) and cell death markers were monitored by immunoblotting (c, g).
Extracellular caspase activity was quantiﬁed using a ﬂuorescent caspase-activity probe (DEVD-AMC) (b). Intracellular caspase activity was quantiﬁed
using a ﬂuorescent caspase-activity probe (DEVD-AMC) after lysing the cells (e). h, i A20−/− MEFs were transfected with siRNA targeting RIPK3 (H) or
MLKL (i) or nonspeciﬁc siRNA (NS). Cells were pretreated with the indicated compounds for 30 min before stimulation with 10 ng/ml mTNF. Cell
death was measured in function of time by SytoxGreen (SG) positivity. j A20+/+ and A20−/− MEFs were pretreated with the indicated compounds for
30 min before stimulation with 10 ng/ml mTNF. The occurrence of apoptotic or necroptotic cell death was determined by FACS analysis. FACS data
represent a representative experiment from three independent experiments. Cell death experiments are presented as mean ± SEM of three
independent experiments. Statistical signiﬁcance for the cell death assays was determined using two-way ANOVA followed by a Tukey post hoc test.
Signiﬁcance between samples is indicated in the ﬁgure as follows: *p < 0.05; **p < 0.01; ***p < 0.001; ns non signiﬁcant.
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therefore indicate that A20 exerts its antideath function
downstream of cIAP1/2, and upstream or parallel to the
prosurvival roles played by IKKα/β, TBK1, and TAK1. In
line with the notion that A20 relies on cIAP1/2 to mediate
its prosurvival function, we observed that A20 was not
recruited to TNFR1 Complex I in cIAP1/2-depleted
conditions (Fig. 3i). Altogether, these results show that
constitutively expressed A20 exerts its antiapoptotic
function independently of NF-κB regulation, but through
cIAP1/2-dependent recruitment to TNFR1 Complex I.
Constitutively expressed A20 protects cells from TNF-
induced death by stabilizing M1-ubiquitin chains in
Complex I
cIAP1/2 are at the origin of the ubiquitin network
associated with Complex I. They generate K63-ubiquitin
Fig. 2 A20 protects intestinal epithelial cells in vitro and in vivo against TNF-induced RIPK1 kinase-dependent and -independent
apoptosis. a, b A20+/+ Ripk1+/+ (n= 7), A20+/+ Ripk1D138N/D138N (n= 5), A20ΔIEC Ripk1+/+ (n= 9), and A20ΔIEC Ripk1D138N/D138N (n= 9) were injected
i.p. with 5 µg/20 g mTNF. Cumulative survival rates (a) and body temperature (b) were determined in function of time. Temperatures are presented as
mean ± SEM. Statistical signiﬁcance for body temperatures of the mice was determined using two-way ANOVA followed by a Tukey post hoc test.
Survival curves were compared using log-rank Mantel–Cox test. c–e Primary intestinal organoid cultures were obtained from A20+/+ and A20ΔIEC
mice and pretreated with the indicated compounds for 30 min before stimulation with 10 ng/ml mTNF. Cell death was measured by propidium
iodide (PI) and is plotted as the relative mean PI intensity per organoid. Data represent a representative experiment from three independent
experiments and are presented as mean ± SD. d Representative images for A20ΔIEC organoid cultures stained with Hoechst and PI after 6 h of mTNF
stimulation. f Primary intestinal organoid cultures were obtained from mice with indicated genotypes and pretreated with the indicated compounds
for 30 min before stimulation with 10 ng/ml mTNF. Cell death was measured by propidium iodide (PI) and is plotted as the relative mean PI intensity
per organoid. Data represent a representative experiment from three independent experiments and are presented as mean ± SD. Signiﬁcance
between samples is indicated in the ﬁgure as follows: *p < 0.05; **p < 0.01; ***p < 0.001; ns non signiﬁcant.
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chains on TNFR1-associated adapter proteins that in turn
allow the conjugation of M1 chains to Complex I com-
ponents by LUBAC. Together, these ubiquitin chains
ensure cell survival by recruiting TAK1, IKKα/β, and
TBK1 to the TNFR1 signaling complex7,9,10,14,43. Having
established that A20 exerts its antideath function down-
stream of cIAP1/2, we evaluated the effect of A20-
deﬁciency on the ubiquitin network associated with
Complex I. We found that A20−/−MEFs have a clear defect
in M1-ubiquitylation, as monitored by immunoblotting
FLAG-immunoprecipitated Complex I for M1-ubiquitin or
by direct immunoprecipitation of M1-ubiquitin chains
using UBANs7 (Fig. 4a, S4A). The difference in M1-
ubiquitylation between A20 proﬁcient and deﬁcient cells
was maintained even upon CHX pretreatment, demon-
strating that constitutively expressed A20 is responsible to
maintain high levels of linear ubiquitin chains in Complex I
(Fig. 4b). In contrast, A20-deﬁciency led to more K63-
ubiquitylated proteins in Complex I, in part illustrated by
RIPK1's ubiquitylation pattern (Fig. 4a). Treatment of
immunoprecipitated Complex I with the deubiquitylase
USP2 and with the λ-phosphatase demonstrated that the
defects in ubiquitylation were not the result of impaired
recruitment of the LUBAC subunit HOIP, or of the ubi-
quitylated substrates RIPK1, TRADD, or TNFR1 (Fig. 4c).
To evaluate the domains of A20 implicated in the
observed phenotype, we stably reconstituted A20-
deﬁcient MEFs with wild type (WT) A20 or with ver-
sions of A20 mutated in the OTU (DUB inactive), ZF4 (E3
inactive), or ZF7. We found that mutating any of these
domains led to an accumulation of K63-ubiquitin chains
in Complex I, but that only the ZF7 mutant additionally
diminished M1-ubiquitylation (Fig. 4d), thereby further
mimicking full loss of A20. In order to correlate the
defects in ubiquitylation to cell death induction, we
monitored the death response of these cells to single
TNF stimulation. Interestingly, the ZF7 mutant was the
only one recapitulating the sensitization observed in
cells depleted of A20 (Fig. 4e). Indeed, the cell death did
not signiﬁcantly differ between cells re-expressing WT
A20 and the ZF4- or OTU-mutants (Fig. 4e). We also
found that mutating the ZF7 domain, but not the ZF4
or OTU domains, prevented recruitment of A20 to
TNFR1 Complex I (Fig. 4f). Together, these results
therefore demonstrated direct correlation between
impaired recruitment to Complex I, defective M1-
ubiquitylation in Complex I and cell death induction. In
addition, these results also demonstrated that the pro-
tective role of A20 is mediated by its ZF7 domain,
independently of the functions attributed to its ZF4 and
OTU domains.
We found that, similar to A20−/− MEFs, cells deprived
of linear ubiquitylation by HOIP deletion also suc-
cumbed to single TNF stimulation by RIPK1 kinase-
dependent and -independent apoptosis (Fig. S4B, C),
further supporting the idea that altered M1-
ubiquitylation in Complex I drives apoptosis in A20-
deﬁcient cells. To challenge this hypothesis, we evaluated
the effect of restoring M1-ubiquitylation in A20−/−
MEFs by repressing CYLD, a DUB known to hydrolyze
K63- and M1-ubiquitin chains in the TNFR1 path-
way24,44. Repressing CYLD in A20−/− MEFs partially
restored M1-ubiquitylation in Complex I (Fig. 5a),
reduced cytosolic RIPK1 autophosphorylation on S166
(Fig. 5a), and rescued A20-deﬁcient MEFs and HaCaTs
from TNF-induced RIPK1 kinase-dependent and -inde-
pendent apoptosis (Fig. 5b–e). In contrast, CYLD
depletion failed to rescue HOIP-deﬁcient cells from
TNF-induced death, supporting an M1-ubiquitin-speciﬁc
effect of CYLD depletion in A20–/– MEFs (Fig. S5A). To
evaluate if the in vitro protective effect observed by
CYLD deletion in A20−/− cells could be translated
in vivo, we generated A20ΔIEC CyldΔIEC mice45. These
mice were signiﬁcantly protected from TNF-induced
intestinal apoptosis when compared to A20ΔIEC mice, as
shown by reduced caspase-3 processing and activity in
small intestinal homogenates (Fig. 5f, g). Nevertheless,
A20ΔIEC and A20ΔIEC CyldΔIEC mice responded similarly
to TNF-induced hypothermia and lethality (Fig. 5h, i),
which could potentially be explained by the cell death-
(see ﬁgure on previous page)
Fig. 3 Constitutively expressed A20 exerts its antideath function through cIAP1/2-dependent recruitment to TNFR1 Complex I. a A20+/+
MEFs were stimulated with 1 µg/ml FLAG-hTNF for the indicated duration. TNFR1 Complex I was FLAG-immunoprecipitated, followed by USP2
treatment on the post-IPs. Protein levels were determined by immunoblotting. b A20+/+ MEFs were pretreated with CHX for 30 min before
stimulation with 10 ng/ml mTNF for the indicated duration. Protein levels were determined by immunoblotting. c–g A20+/+ and A20−/− MEFs were
pretreated with the indicated compounds for 30 min before stimulation with 100 pg/ml (c–f) or 1 ng/ml (g) mTNF. Cell death was measured in
function of time by SytoxGreen (SG) positivity. h ciap1/2−/− MEFs were transfected with siRNA targeting A20 or nonspeciﬁc siRNA (NS). Cells were
stimulated with 1 ng/ml mTNF. Cell death was measured in function of time by SytoxGreen (SG) positivity. i ciap1/2+/+ and ciap1/2−/− MEFs were
stimulated with 1 µg/ml FLAG-hTNF for the indicated duration. TNFR1 Complex I was FLAG-immunoprecipitated, followed by USP2 treatment on the
post-IPs. Protein levels were determined by immunoblotting. Cell death experiments are presented as mean ± SEM of three independent
experiments. Statistical signiﬁcance for the cell death assays was determined using two-way ANOVA followed by a Tukey post hoc test. Signiﬁcance
between samples is indicated in the ﬁgure as follows: *p < 0.05; **p < 0.01; ***p < 0.001; ns non signiﬁcant.
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independent excessive inﬂammation resulting from the
combined removal of these DUBs. Together, our results
support a model in which constitutively expressed A20
protects cells from TNF-induced RIPK1 kinase-
dependent and -independent apoptosis by antagonizing
the CYLD-mediated degradation of the linear ubiquitin
network associated to Complex I.
A20 additionally protects cells from TNF-induced death
independently of linear ubiquitylation
To determine if A20 additionally protects cells by a
mechanism independent of M1-ubiquitylation, we
repressed A20 in HOIP-depleted cells. Remarkably, A20
inactivation further sensitized HOIP-depleted MEFs and
HaCaT cells to TNF-induced death (Fig. 6a–c). In line
Fig. 4 Constitutively expressed A20 protects cells from TNF-induced death via its ZF7 domain by stabilizing M1-linked ubiquitin chains in
TNFR1 Complex I. a A20+/+ and A20−/− MEFs were stimulated with 1 µg/ml FLAG-hTNF for the indicated duration. TNFR1 Complex I was subsequently
FLAG-immunoprecipitated. Protein levels were determined by immunoblotting. b A20+/+ and A20−/− HaCaTs were pretreated with CHX for 30min
before stimulation with 1 µg/ml FLAG-hTNF for the indicated duration. TNFR1 Complex I was subsequently FLAG-immunoprecipitated. Protein levels were
determined by immunoblotting. c A20+/+ and A20−/− MEFs were stimulated with 1 µg/ml FLAG-hTNF for the indicated duration. TNFR1 Complex I was
FLAG-immunoprecipitated, followed by USP2+ ƛ-phosphatase treatment on the post-IPs. Protein levels were determined by immunoblotting. d A20−/−
MEFs lentivirally reconstituted with wild-type A20, empty vector (EV) or indicated A20 mutants were stimulated with 1 µg/ml FLAG-hTNF for the indicated
duration. TNFR1 Complex I was subsequently FLAG-immunoprecipitated. Protein levels were determined by immunoblotting. e A20−/− MEFs lentivirally
reconstituted with wild-type A20, empty vector (EV) or indicated A20 mutants were stimulated with 1 ng/ml mTNF and cell death was measured in
function of time by SytoxGreen (SG) positivity. f A20−/− MEFs lentivirally reconstituted with wild-type A20, empty vector (EV) or indicated A20 mutants
were stimulated with 1 µg/ml FLAG-hTNF for the indicated duration. TNFR1 Complex I was subsequently FLAG-immunoprecipitated, followed by USP2
treatment on the post-IPs. Protein levels were determined by immunoblotting. Cell death experiments are presented as mean ± SEM of three
independent experiments. Statistical signiﬁcance for the cell death assays was determined using one-way ANOVA followed by a Dunnett post hoc test.
Signiﬁcance between samples is indicated in the ﬁgure as follows: *p < 0.05; **p < 0.01; ***p < 0.001; ns non signiﬁcant.
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(see ﬁgure on previous page)
Fig. 5 CYLD depletion rescues defective M1-ubiquitylation in Complex I and consequently protects A20-deﬁcient cells from TNF-induced
apoptosis. a A20+/+ and A20−/− MEFs were transfected with siRNA targeting CYLD or non-speciﬁc siRNA (NS) and stimulated with 1 µg/ml FLAG-
hTNF for the indicated duration. TNFR1 Complex I was subsequently FLAG-immunoprecipitated. Protein levels were determined by immunoblotting.
b–d A20−/− MEFs were transfected with siRNA targeting CYLD or nonspeciﬁc siRNA (NS). Cells were pretreated with the indicated compounds for
30 min before stimulation with 10 ng/ml mTNF. Cell death markers were monitored by immunoblotting (b) and cell death was measured in function
of time by SytoxGreen (SG) positivity (c, d). e A20−/− HaCaTs were transfected with siRNA targeting CYLD or nonspeciﬁc siRNA (NS). Cells were
pretreated with CHX for 30 min before stimulation with 10 ng/ml hTNF. Cell death was measured in function of time by SytoxGreen (SG) positivity.
f, g A20+/+ Cyld+/+ (n= 3), A20ΔIEC Cyld+/+ (n= 3), and A20ΔIEC Cyld ΔIEC (n= 3) were injected i.p. with 5 µg/20 g mTNF. Caspase activity was
quantiﬁed from small intestinal tissue homogenates 2 h post injection using a ﬂuorescent caspase-activity probe (DEVD-AMC) (f) or via
immunoblotting (g). h, i A20+/+ Cyld+/+ (n= 5), A20ΔIEC Cyld+/+ (n= 4), and A20ΔIEC Cyld ΔIEC (n= 5) were injected i.p. with 5 µg/20 g mTNF.
Cumulative survival rates (h) and body temperature (i) were determined in function of time. Temperatures are presented as mean ± SEM. Statistical
signiﬁcance for body temperatures of the mice was determined using two-way ANOVA followed by a Tukey post hoc test. Survival curves were
compared using log-rank Mantel–Cox test. Cell death experiments are presented as mean ± SEM of three independent experiments. Statistical
signiﬁcance for the cell death assays was determined using two-way ANOVA followed by a Tukey post hoc test. Signiﬁcance between samples is
indicated in the ﬁgure as follows: *p < 0.05; **p < 0.01; ***p < 0.001; ns non signiﬁcant.
Fig. 6 A20 additionally protects cells from death through its deubiquitylase activity. a Hoip−/− MEFs were transfected with siRNA targeting
A20 or nonspeciﬁc siRNA (NS). Cells were stimulated with 10 ng/ml mTNF and cell death was measured in function of time by SytoxGreen (SG)
positivity. b A20+/+ and A20−/− MEFs were transfected with siRNA targeting HOIP. Cells were stimulated with 10 ng/ml mTNF and cell death was
measured in function of time by SytoxGreen (SG) positivity. c A20+/+ and A20−/− HaCaTs were transfected with siRNA targeting HOIP. Cells were
stimulated with 10 ng/ml hTNF and cell death was measured in function of time by SytoxGreen (SG) positivity. d Hoip+/+ and Hoip−/− MEFs were
stimulated with 1 µg/ml FLAG-hTNF for the indicated duration. TNFR1 Complex I was FLAG-immunoprecipitated, followed by USP2 treatment on the
post-IPs. Protein levels were determined by immunoblotting. e Hoip−/− A20−/− MEFs lentivirally reconstituted with wild-type A20, empty vector (EV)
or indicated A20 mutants were stimulated with 1 µg/ml FLAG-hTNF for the indicated duration. TNFR1 Complex I was subsequently FLAG-
immunoprecipitated, followed by USP2 treatment on the post-IPs. Protein levels were determined by immunoblotting. f A20−/− MEFs lentivirally
reconstituted with wild-type A20, empty vector (EV) or indicated A20 mutants were transfected with siRNA targeting HOIP. Cells were stimulated with
10 pg/ml mTNF and cell death was measured in function of time by SytoxGreen (SG) positivity. Statistical signiﬁcance for the cell death assays was
determined using two-way ANOVA followed by a Tukey post hoc test (a–c) or using one-way ANOVA followed by a Dunnett post hoc test (f).
Signiﬁcance between samples is indicated in the ﬁgure as follows: *p < 0.05; **p < 0.01; ***p < 0.001; ns non signiﬁcant.
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with a protective function of A20 at the level of Complex
I, we found that A20 was still recruited to Complex I early
after TNF stimulation in Hoip−/− MEFs, although to a
much lower extent than in control MEFs (Fig. 6d). In
HOIP-proﬁcient cells, recruitment of A20 to Complex I
was solely depending on its ZF7 (Fig. 4f), which was in
accordance with previous studies reporting speciﬁc
binding of ZF7 to linear ubiquitin chains24,26,37. In
HOIP-deﬁcient cells, we instead found that A20's
recruitment to Complex I became dependent on its ZF4,
but surprisingly also remained dependent on its ZF7
(Fig. 6e). Indeed, the ZF7 mutant, which still has an
intact ZF4, was also unable to associate with Complex I.
These results indicated that, in absence of linear ubi-
quitylation, the ZF4 and ZF7 domains of A20 cooperate
to bind to other types of ubiquitin chains associated to
Complex I, potentially K63-linked chains. In accordance
with the notion that A20 exerts its antideath role in
Complex I, re-expressing WT A20, but not the ZF4 or
ZF7 mutant, provided protection to TNF-induced death
in MEFs simultaneously depleted of HOIP and A20 (Fig.
6f). Interestingly, the OTU mutant also failed to provide
protection in these HOIP-deﬁcient cells, despite the fact
that it was efﬁciently recruited to Complex I (Fig. 6e, f).
Since the OTU domain was not required for A20's
antideath function in HOIP-proﬁcient cells (Fig. 4e),
these results indicate a switch in the molecular
mechanism employed by A20 to protect the cells from
death in conditions of defective M1-ubiquitylation.
Taken together, our results demonstrate that in normal
conditions, constitutively expressed A20 protects the cells
from TNF-induced apoptosis by ZF7-dependent binding
to the linear ubiquitin chains associated to Complex I, and
thereby protecting them from CYLD-mediated degrada-
tion. In contrast, in absence of M1-ubiquitylation, the
protective role of A20 relies on its ZF4/ZF7-dependent
recruitment to Complex I, and on the deployment of its
deubiquitylase activity (Fig. 7a, b).
Discussion
In this study, we characterized the prosurvival role of
A20 in cells exposed to TNF, and evaluated some of our
in vitro ﬁndings in an in vivo model of lethal inﬂamma-
tion induced by the administration of low doses of TNF to
Fig. 7 Schematic overview of the prosurvival functions of A20. a M1-ubiquitylation-proﬁcient cells: A20 protects cells from TNF-mediated
apoptosis by antagonizing CYLD-mediated degradation of M1-ubiquitin chains. Binding of TNF to TNFR1 induces the formation of TNFR1 Complex I.
The E3 ubiquitin ligases cIAP1/2 conjugate Complex I components with ubiquitin chains of different types, including K63-linked chains. The
multiprotein E3 complex LUBAC docks on these newly formed K63-linked chains to further conjugate Complex I components with M1-linked (linear)
ubiquitin chains; creating, in some cases, hybrid K63/M1 chains. Within minutes of TNF sensing, constitutively expressed A20 is recruited to Complex I
via the binding of its ZF7 domain to ubiquitin chains of different types, including M1-linked chains. Recruited A20 promotes cell survival by
antagonizing CYLD-mediated hydrolysis of the M1-linked ubiquitin chains in the complex. In conditions of A20 deﬁciency, CYLD dismantles the M1-
linked ubiquitin network, ultimately inducing RIPK1 kinase-dependent and -independent apoptosis. b In absence of M1-ubiquitylation: A20 protects
cells from TNF-induced apoptosis by deubiquitylating a yet to be identiﬁed substrate. Constitutively expressed A20 is still recruited to Complex I in
absence of M1-ubiquitylation through ZF4/ZF7-mediated binding to the residual ubiquitin chains, potentially the K63-linked chains. Recruited A20
limits the extent of TNF-induced apoptosis by deubiquitylating unknown substrate(s). The DUB activity of A20 may counteract the K48-ubiquitin-
mediated proteasomal degradation of a prosurvival molecule and/or the K63-ubiquitin-dependent stabilization of a prodeath signaling platform.
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mice speciﬁcally lacking A20 in IECs (A20ΔIEC)39. We
found that A20 deﬁciency sufﬁces to sensitize MEFs and
intestinal organoids to TNF-induced death in the absence
of any additional inhibitor of the TNFR1 pathway. We
found that A20 deﬁciency results in the simultaneous
occurrence of RIPK1 kinase-dependent and -independent
apoptosis, but not in the spontaneous induction of
necroptosis. In line with these in vitro and ex vivo results,
genetic inhibition of RIPK1 kinase activity, but not RIPK3
deﬁciency, signiﬁcantly delayed the lethality of A20ΔIEC
mice injected with TNF. These results demonstrate the
contribution of RIPK1 kinase-dependent apoptosis, and
not necroptosis, to the lethal inﬂammatory phenotype of
A20ΔIEC mice exposed to TNF. RIPK1 kinase-dependent
cell death is reported to drive the pathogenesis of several
inﬂammatory diseases in the mouse, and RIPK1 inhibitors
are now in clinical trials for the treatment of inﬂammatory
bowel disease (IBD), psoriasis, and rheumatoid arthritis46.
The fact that the A20ΔIEC Ripk1D138N/D138N mice still died
at a later stage in our experiment may limit the enthu-
siasm for the potential use of RIPK1 inhibitors in IBD
patients harboring A20 mutations. The lethality of the
A20ΔIEC Ripk1D138N/D138N mice can potentially be
explained by the remaining occurrence of RIPK1 kinase-
independent apoptosis of IECs, but also by the excessive
NF-κB signaling originating from A20 deﬁciency.
The TNF-mediated NF-κB-dependent upregulation of
A20 is widely considered as an inhibitory feedback
mechanism to shut down NF-κB activation. An accepted
model is that upregulated A20 is recruited to TNFR1
Complex I to mediate its inhibitory role on NF-κB acti-
vation. Our results show that constitutively expressed A20
is also recruited to the TNFR1 Complex I within minutes
of TNF sensing; thus, far before the pool of de novo
synthesized A20. Importantly, we show that the pool of
constitutively expressed A20 protects cells from TNF-
induced death independently of the upregulated A20. This
may indicate that two different pools of A20 respectively
regulate cell death and NF-κB activation, thereby
uncoupling these two functions of A20. We can however
not exclude the possibility that the de novo synthesized
A20 also contributes to A20's prosurvival function.
We show that association of constitutively expressed
A20 to Complex I occurs in a cIAP1/2-dependent manner
and is solely mediated by A20's ZF7 domain under HOIP-
proﬁcient conditions. In line with a previous report24, we
found that removal of A20, or preventing its recruitment
to Complex I by mutating its ZF7, results in increased cell
death, and is associated with increased K63-ubiquitylation
and decreased M1-ubiquitylation of Complex I compo-
nents. We now demonstrate that the defective M1-
ubiquitylation of Complex I is responsible for the
induction of RIPK1 kinase-dependent and -independent
apoptosis in A20-deﬁcient cells. Indeed, we ﬁrst excluded
the increase in K63-ubiquitylation as a driver of cell death
by showing that mutation in A20's ZF4 or OTU domains
also resulted in elevated K63-ubiquitylation but without
sensitizing the cells to death. Those results also demon-
strated that the E3 ubiquitin ligase and deubiquitylase
activities of A20 are not required to protect these cells
from death. Then, by deleting CYLD in A20-deﬁcient
cells, we were able to partially restore the M1-linked
ubiquitin chains and revert the sensitivity towards TNF-
mediated cell death, thereby demonstrating that reduced
M1-ubiquitylation of Complex I causes death in A20-
deﬁcient cells. We found that IEC-speciﬁc CYLD deletion
protected A20ΔIEC mice from TNF-induced intestinal
apoptosis, indicating that this mechanism also occurs
in vivo. However, we did not observe reduced or delayed
lethality of A20ΔIEC CyldΔIEC mice upon TNF injection. It
is important to note that A20ΔIEC CyldΔIEC mice lack two
potent NF-κB repressors and, consequently, TNF
administration to these mice may trigger massive NF-κB-
dependent inﬂammation that drives the observed leth-
ality. Together, our results highlight a complex interplay
between A20 and CYLD in regulating life-death decisions
by ﬁnetuning M1-linked ubiquitin chains in TNFR1
Complex I (Fig. 7a).
Our data reveals that Complex I-associated M1-ubiqui-
tin chains regulate both RIPK1 kinase-dependent and
-independent death. Linear ubiquitylation-dependent
phosphorylation of RIPK1 by IKKα/β and TBK1/IKKε
was recently reported to repress RIPK1 activation and
RIPK1 kinase-dependent apoptosis9,10,14,47. Accordingly,
we found that the reduced M1-ubiquitylation caused by
A20 deﬁciency activates RIPK1 and triggers RIPK1 kinase-
dependent apoptosis. How defective M1-ubiquitylation
additionally promotes RIPK1-independent apoptosis is less
clear. The NF-κB-dependent upregulation of prosurvival
proteins is known to protects cells from RIPK1-
independent apoptosis15,43. In light of the reported role
of linear ubiquitylation as docking site for NEMO-IKKα/β
activation, it would be easy to explain the induction of
RIPK1-independent apoptosis by a defect in NF-κB sig-
naling. The problem resides on the fact that A20-
deﬁciency instead leads to sustained NF-κB activation.
As a potential alternative mechanism, we can envision that
reduced M1-ubiquitylation destabilizes Complex I and
thereby facilitates dissociation of its components for their
subsequent association into the RIPK1-independent
apoptosis-inducing Complex IIa. The discrepancy
between reduced M1-ubiquitylation of Complex I and the
sustained NF-κB activation observed in absence of A20
may instead be explained by the increase in K63-ubiqui-
tylation, which would somehow compensate for the
missing M1-ubiquitin linkages.
We found that the ability of A20 to protect cells from
death is not limited to antagonizing the degradation of
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M1-ubiquitin chains by CYLD. Indeed, A20 is still
recruited to Complex I in cells lacking M1-ubiquitylation,
where it acts as a molecular brake limiting the extent of
cell death by deploying its DUB activity (Fig. 7b). In M1-
proﬁcient cells, recruitment of A20 to Complex I was
solely depending on its ZF7, known to preferentially bind
M1-ubiquitin chains26,28. In absence of M1-ubiquityla-
tion, recruitment of A20 to Complex I became dependent
on its ZF4 and ZF7. These results indicate that the ZF7
domain, unlike widely assumed, does not exclusively bind
M1-ubiquitin chains, and that the ZF4 and ZF7 can
cooperate in binding to other types of ubiquitin chains
associated to Complex I, potentially K63-linked chains.
We found that both the ZF4 and ZF7 domains of A20
were required to provide protection to TNF-induced
death in HOIP-depleted MEFs, indicating that A20 also
exert its anti-death role in Complex I in these cells.
Interestingly, the requirement of A20's DUB activity to
protect cells from death was only observed in M1-
ubiquitylation-deﬁcient cells. This indicates a switch in
the molecular mechanism employed by A20 to protect
the cells in these two different conditions. In M1-
proﬁcient cells, A20's prosurvival function consists in
antagonizing CYLD-mediated degradation of M1-
ubiquitin chains, potentially just by binding to the linear
chains via its ZF7 domain, as previously suggested24,26,37.
In absence of M1-ubiquitylation, recruitment of A20 to
Complex I limits the extent of cell death by deubiquity-
lating yet to be identiﬁed substrate(s). Since A20 was
reported to possess DUB activity towards K48- and K63-
ubiquitin linkages21–23, this additional prosurvival role
may counteract the K48-ubiquitin-mediated proteasomal
degradation of a prosurvival molecule and/or the K63-
ubiquitin-dependent stabilization of a prodeath signaling
platform. Identifying the substrate(s) of A20's DUB
activity in this context therefore represents an exciting
challenge.
Together, our results demonstrate two distinct mole-
cular mechanisms by which constitutively expressed A20
protect cells from TNF-induced apoptosis, thereby pro-
viding new insights on the complexity of this potent anti-
inﬂammatory molecule.
Materials and methods
Antibodies and reagents
The following antibodies were used throughout this
manuscript: anti-A20 (Santa Cruz sc-166692, 1:1000), anti-
RIPK1 (BD Biosciences #610459, 1:2000; Cell Signaling
#3493, 1:2000), anti-IκBα (Santa Cruz sc-371, 1:2000), anti-
β-tubulin-HRP (Abcam ab21058, 1:10000), anti-phospho
Ser166 RIPK1 (Cell Signaling #31122, 1:1000), anti-cleaved
caspase-8 (Cell Signaling #9429, 1:1000), anti-caspase-8
(Abnova MAB3429, 1:1000), anti-caspase-3 (Cell Signaling
#9662, 1:1000), anti-PARP (Cell Signaling # 9532S, 1:1000),
anti-cleaved PARP (Cell Signaling #9544S, 1:1000), anti-
phospho Ser345 MLKL (Millipore MABC1158, 1:1000),
anti-MLKL (Millipore MABC604, 1:1000), anti-TRADD
(Bio-Rad AHP2533, 1:1000), anti-RIPK3 (ProSci #2283,
1:3000), anti-CYLD (Santa Cruz sc-74435, 1:500), ant-
cIAP1 (Enzo Life Science ALX-803-335-C100, 1:1000), anti-
TNFR1 (Cell Signaling #13377, 1:1000), anti-HOIP (Abcam
ab46322, 1:1000), anti-M1-ubiquitin (1E3Merck MABS199,
LUB9 Merck MABS451, 1:1000), and anti-K63-ubiquitin
(Apu3 Merck #05-1308). Recombinant mouse and human
TNF-α (concentration indicated in the ﬁgure legends) and
FLAG-tagged hTNF (1 μg/ml) were purchased from the
VIB Protein Service Facility (Ghent, Belgium). Rat
recombinant untagged USP2 was purchased from Enzo
Life Sciences (BML-UW9850-0100). Lambda protein
phosphatase was obtained from New England Biolabs
(P0753s). The following compounds were used: IKKi
(TPCA-1, 5 μM, Tocris Bioscience), zVAD-fmk (50 μM,
Bachem), CHX (2 µg/ml, Sigma-Aldrich), TBKi
(MRT67307, 2 µM, Bioconnect; GSK8612, 10 µM, Med-
ChemExpress), TAK1i (5Z-7-Oxozeaenol, 500 nM, Ana-
lyticon Discovery), BV6 (1 μM, Selleckchem), Staurosporin
(2 µM, Sigma), Etoposide (10 µM, Enzo Life Sciences),
ML-162 (10 µM, Aobious Inc), Tunicamycin (10 µg/ml,
Sigma), and Doxycycline (1 µg/ml, Sigma). Nec-1s
(UAMC-02197) was produced by the Laboratory of
Medicinal Chemistry (University of Antwerp, Belgium).
Mice
A20ΔIEC, Ripk1D138N/D138N, and Cyldﬂ/ﬂ mice were
described earlier39,40,45. A20ΔIEC CyldΔIEC mice were
generated by crossing the Cyldﬂ/ﬂ mice with the A20ΔIEC
mice (expressing Cre under the Villin promotor), ulti-
mately generating mice speciﬁcally lacking A20 and
CYLD in intestinal epithelial cells. All crosses were vali-
dated by genotyping. Primary cultures were isolated from
littermate mice.
TNF shock model
All experiments on mice were conducted according to
institutional, national and European animal regulations.
Animal protocols were approved by the ethical committee
of Ghent University. For the TNF shock model, 5 μg/20 g
mTNF (diluted in endotoxin-free phosphate-buffered
saline (PBS) (pH 6.8)) was intraperitoneally (i.p.) injected.
Mortality and body temperature were monitored until
24 h after mTNF injection. Rectal body temperature was
recorded with an industrial electric thermometer
(Comark Electronics, Norwich, UK; model 2001). Dead
mice were considered to be at 25 °C.
Cell lines and primary cultures
Mouse embryonic ﬁbroblasts (MEFs) and mouse dermal
ﬁbroblasts were cultured in Dulbecco’s modiﬁed Eagle’s
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medium supplemented with 10% fetal calf serum, L-glu-
tamine (200mM) and sodium pyruvate (400mM) in nor-
moxic conditions (5% CO2). When the cells were still at
the primary state, 0.1% β-mercaptoethanol and 100 ng/ml
penicillin/streptomycin was added to the medium. Pri-
mary A20+/+ and A20−/− MEFs were isolated from E12.5
littermate embryos following standard protocol and cul-
tured under low-oxygen conditions (3% O2). MEFs were
subsequently immortalized by an SV40-containing con-
struct with JetPRIME (Polyplus transfection) according the
manufacturer’s instructions. Hoip−/− Tnf −/− and Hoip+/+
Tnf −/− MEFs were a kind gift from Prof. H. Walczak.
Hoip−/− A20−/− Tnf −/− MEF cells were generated using
CRISPR/Cas9. In short, Hoip−/− Tnf −/− MEF cells were
transfected with a plasmid encoding Cas9 nuclease and a
guide sequence targeting mouse A20 (GGAGCTTGT-
CAGTACATGTG), subcloned and screened for A20
deﬁciency. Human immortalized keratinocytes (HaCaTs)
were cultured in Dulbecco’s modiﬁed Eagle’s medium
supplemented with 10% fetal calf serum and L-glutamine
(200mM). A20-deﬁcient HaCaT cells were generated
using CRISPR/Cas9. In short, WT HaCaT cells were
transfected with a plasmid encoding Cas9 nuclease and a
guide sequence targeting human A20 (TGGAT-
GATCTCCCGAAACTG), subcloned and screened for
A20 deﬁciency. Intestinal organoids were derived from
small intestine as previously described48. Brieﬂy, a 5-cm
piece of duodenum/jejunum was dissected and washed in
PBS. The intestine was opened longitudinally, villi were
scraped away, and the tissue was chopped into pieces of
2–3mm. After thorough washing in PBS, the pieces were
incubated in 2mM EDTA/PBS for 30 min at 4 °C on a
rocking platform. The mixture was passed through a 70-
µm cell strainer, and crypt fractions were isolated and
puriﬁed by successive centrifugation steps. One milliliter
of Matrigel (BD Biosciences) was added to a pellet of
100–1000 crypts, and 50-µl drops of crypt-containing
Matrigel were added to prewarmed wells in a 24-well
plate. After polymerization, 500 µl complete growth
medium containing EGF (Peprotech), R-Spondin1 (R&D),
and Noggin (Peprotech) was added and refreshed every
2 days.
RNA interference
MEFs were seeded at 1 × 105 cells per well in 6-well
plates. The cells were transfected 24 h later with speciﬁc
siRNAs using Dharmafect1 (Dharmacon) according to the
manufacturer’s instructions. Cells were reseeded in
appropriate plates 24 h post transfection and analyzed
48 h post transfection. For silencing genes in HaCaTs,
3000 cells were seeded per well in triplicates in a 96-well
plate. The cells were immediately transfected with speciﬁc
siRNA using INTERFERin (Polyplus transfection)
according to the manufacturer’s instructions. Medium
was changed 24 h post transfection and cells were ana-
lyzed 48 h post transfection. All siRNA’s were purchased
from Dharmacon (ON-TARGETplus SMARTpool),
except siRNA targeting mouse A20 (Ambion).
Cell death assays
For cell death assays in MEFs, cells were seeded the day
before at 10,000 per well in triplicates in a 96-well plate.
Cells reconstituted with A20 mutants were treated with
1 µg/ml doxycycline 24 h prior to stimulation. The next
day, cells were pretreated with the indicated compounds
for 30min and then stimulated with the indicated con-
centration of mTNF in the presence of 2,5 μM SytoxGreen
(Invitrogen) and 20 μM Ac-DEVD-MCA (PeptaNova).
SytoxGreen intensity and caspase-3 activation were mea-
sured at intervals of 1 h using a Fluostar Omega ﬂuores-
cence plate reader, with an excitation ﬁlter of 485 nm
(SytoxGreen) or 360 nm (Ac-DEVD-MCA), an emission
ﬁlter of 520 nm (SytoxGreen) or 460 nm (Ac-DEVD-
MCA), gains set at 1100, 20 ﬂashes per well and orbital
averaging with a diameter of 3 mm. Percentage of cell
death was calculated as (induced ﬂuorescence− back-
ground ﬂuorescence)/(maximum ﬂuorescence− back-
ground ﬂuorescence) × 100. The maximal ﬂuorescence is
obtained by full permeabilization of the cells by using
Triton X-100 at a ﬁnal concentration of 0.1%. All cell
death and caspase-3 activation data are presented as
mean ± SEM of n (indicated in the ﬁgure) independent
experiments, unless stated otherwise. For intracellular
caspase-activity measurement, cells were seeded the day
before at 10,000 per well in triplicates in a 96-well plate.
The next day, cells were pretreated with the indicated
compounds for 30min and then stimulated with the
indicated concentration of mTNF. Cells were lysed in
caspase lysis buffer (1% NP-40, 200mM NaCl, 10 mM
Tris-HCl pH 7, 5 mM EDTA, 10% glycerol, freshly sup-
plemented with 1 mM leupeptin, 0.1 mM aprotinin and
1mM PMSF) and volume was adjusted to reach a protein
concentration of 2 µg/µl. A 20 µg of cell lysate was added
to 140 µl of CFS buffer (10 mM HEPES pH 7.5, 220mM
mannitol, 68 mM sucrose, 2 mM NaCl, 2 mM MgCl2,
2.5 mM KH2PO4, freshly supplemented with 10mM
DTT) containing 50 µM Ac-DEVD-MCA (PeptaNova).
Caspase-3 activation was measured at intervals of 5 min
using a Fluostar Omega ﬂuorescence plate reader, as
described above. To measure cell death in HaCaTs, cells
were seeded the day before at 10,000 per well in triplicates
in a 96-well plate. The next day, cells were pretreated with
the indicated compounds for 30min and then stimulated
with the indicated concentration of hTNF in the presence
of 1 μM SytoxGreen (Invitrogen). SytoxGreen (SG) posi-
tivity was measured at intervals of 1 h using an Essen
BioScience IncuCyte. Percentage of cell death was calcu-
lated as (number of SG+ cells/mm2− number of
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unstimulated SG+ cells/mm2)/(maximum number of
SG+ cells/mm2− number of unstimulated SG+ cells/
mm2) × 100. To measure cell death in organoid cultures,
primary organoids were isolated and plated in triplicates
in a 96-well plate. Five days later, organoids were pre-
treated with the indicated compounds for 30min and
then stimulated with the indicated concentration of
mTNF in the presence of 3 μM propidium iodide (PI)
(Sigma) and 1.6 μM Hoechst (Invitrogen). Cells were
imaged at intervals of 1 h using a PerkinElmer Operetta
High-Content Imaging System. Organoids were deﬁned
based on size, shape and Hoechst positivity. Cell death
was calculated by mean PI intensity per organoid. To
analyze cell death by FACS, 3 × 105 cells were seeded in a
21 cm2 petridish per condition. The next day, cells were
pretreated with the indicated compounds for 30min and
then stimulated with the indicated concentration of
mTNF. After stimulation, cells+ supernatant was col-
lected, washed and stained with DRAQ7 (500 nM, Bios-
tatus) and CellEvent Caspase-3/7 Green activity probe
(500 nM, Life Technologies) for 45′ at RT. Cell death
stainings were measured using a 752 LP ﬁlter (DRAQ7)
and 507 LP ﬁlter (Caspase-3/7 Green) on the
FACSVerse (BD).
Production of GST-UBAN
Recombinant GST-UBAN were produced in BL21(DE3)
cells. In brief, BL21(DE3) cells were transformed with the
plasmid encoding GST-UBAN and protein expression
was induced with 0.5M IPTG. After 4 h, cells were col-
lected and lysed in lysis buffer (20 mM Tris-HCl pH 7.5,
10 mM EDTA, 5 mM EGTA, 150mM NaCl, 1 mM DTT
supplemented with phosphatase and protease inhibitor
cocktail tablets (Roche Diagnostics)), sonicated and
cleared by centrifugation. After centrifugation, Triton-
X100 (0.5% ﬁnal concentration) was added to the super-
natant, which was then transferred onto prewashed glu-
tathione beads and left rotating for 2 h at 4 °C. After
incubation, the beads were centrifuged, washed twice with
washing buffer (20 mM Tris-HCl pH 7.5, 10 mM EDTA,
150mM NaCl, 0.5% Triton-X100) and resuspended in
resuspension buffer (20 mM Tris-HCl pH 7.5, 0.1%
β-mercaptoethanol, 0.05% sodiumazide), ready to be used.
Immunoprecipitation
TNFR1 Complex I was isolated as described49. In brief,
8 × 106 cells were seeded in a 150 cm2 petridish per con-
dition for both TNFR1 complex I (CI IP) and M1-
ubiquitin (UBAN IP) IPs. Cells reconstituted with A20
mutants were treated with 1 µg/ml doxycycline 24 h prior
to stimulation. Cells were pretreated as indicated in the
ﬁgure legends and subsequently cells stimulated (or not)
with 1 μg/ml FLAG-hTNF (CI IP) or 1 μg/ml hTNF
(UBßAN IP). Cells were then washed 2 times in ice-cold
PBS and lysed in 1 ml NP-40 lysis buffer (10% glycerol, 1%
NP-40, 150 mM NaCl and 10mM Tris-HCl pH 8 sup-
plemented with phosphatase and protease inhibitor
cocktail tablets (Roche Diagnostics)) (C1) or 1 ml RIPA
lysis buffer (150 mM NaCl, 1% NP-40, 0.5% sodium
deoxycholate, 0.1% SDS, 10 mM Tris-HCl pH 8 supple-
mented with phosphatase and protease inhibitor cocktail
tablets (Roche Diagnostics)) (UBAN IP). The cell lysates
were cleared by centrifugation for 15min at 4 °C and the
supernatants were then incubated overnight with FLAG
M2 afﬁnity gel (Sigma-Aldrich) for CI IPs, or with GST-
UBAN-containing glutathione beads (UBAN IP). The
next day, the beads were washed three times in NP-40
(C1) or RIPA (UBAN IP) lysis buffer. For C1 IPs, the
proteins were eluted from the beads using 200 ng/ml 3×
FLAG peptide. Lysate or beads were then resuspended in
60 μL 1× laemmli buffer for direct analysis. However,
when indicated, protein complexes were additionally
deubiquitylated (by USP2 treatment) and depho-
sphorylated (by lambda protein phosphatase treatment)
post-IP. To do so, beads were resuspended after the ﬁnal
wash step in 50 μL 1× DUB/λPP buffer (50 mM Tris-HCl
pH8, 50 mM NaCl, 5 mM DTT and 1mM MnCl2). Sub-
sequently, 1.2 μg USP2 (Enzo Life Sciences) and 400U λ
PPase were added when indicated. Enzymatic reactions
were allowed to proceed for 30 min at 37 °C and subse-
quently quenched by the addition of 12.5 μl 5× laemmli
buffer. All IPs were analyzed by immunoblotting.
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